| Revenue growth | Total income stood at 411 crore for Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 19.3%, impacted by new hospital operational drag. |
| Demand visibility | Strong demand-supply gap for organized healthcare in Western India. |
| Management confidence | Balanced; focused on execution of announced projects and Dombivli ramp-up. |
Growth
Revenue reached 411 crore with 19.3% EBITDA margin; mature units see inflation-linked growth while new units grow faster.
Outlook
Management expects Dombivli to break even in the second year of operations (FY28).
Risks
Expansion risks include a 6-7 crore monthly fixed cost at Dombivli and potential margin compression during capacity additions.
Last quarter's promises, checked
Delivered
- Commission Dombivli by Q1 FY27 → Opened ahead of schedule in Feb 2026 (= BEAT)
- Build 1,700 new beds at INR 1.5cr/bed → Maintained average cost guidance (= BEAT)
- Maintain net cash positive status → Gross debt 500cr vs 545cr cash (= BEAT)
Partly delivered
- Indore occupancy target 60% for Phase 2 → Delivered 45-50% (= PARTIAL)
- Dombivli EBITDA burn 2-3cr/month → Actual Q1 drag 9.5cr (~3.1cr/month) (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: JLHL. Summary written with AI assistance from the document.
Jupiter Life Line Hospitals Ltd: key numbers
- Share price
- ₹248.55
- Market cap
- ₹8,148 Cr
- Revenue (annual)
- ₹1,500 Cr
- Net profit (annual)
- ₹194.0 Cr
- P/E (TTM)
- 43.4×Sector 53.1×
- Promoter holding
- 40.91%+0.00% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jupiter Life Line Hospitals Ltd
All →Jupiter Life Line Hospitals Other Announcement
Jupiter Life Line Hospitals Limited has authorized specific Key Managerial Personnel for determining and disclosing material events under SEBI Regulation 30(5).
Jupiter Life Line Hospitals Management Change
Jupiter Life Line Hospitals Limited has appointed Mr. Harshad Gaurishankar Purani as the new Chief Financial Officer, effective July 31, 2026.
Jupiter Life Line Hospitals Merger & Restructuring Worth ₹3.78 Cr
Jupiter Life Line Hospitals' subsidiary, Jupiter Hospital Pharmacy, acquired 100% of Sulcus Private Limited for ₹3.78 Crore. This move aims to expand pharmaceutical manufacturing capabilities.
- Value
- ₹3.78 Cr
Jupiter Life Line Hospitals Investor Presentation: Key Takeaways
Jupiter Life Line Hospitals reported Q1FY27 revenue growth of 16.2% YoY, while PAT declined 14.7% due to higher depreciation and finance costs from the new Dombivli facility.
Jupiter Life Line Hospitals Q1 FY27 Results: Net Profit ₹37.5 Cr, Down 14.6% YoY
Jupiter Life Line Hospitals Ltd reported revenue from operations of ₹411 Cr (+16.4% YoY) and net profit of ₹37.5 Cr (-14.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹37.5 Cr · -14.6% YoY
Jupiter Life Line Hospitals Share Pledge
Catalyst Trusteeship Ltd disclosed the creation of a pledge over 1,67,59,750 equity shares of Jupiter Life Line Hospitals Ltd.